Implications for prediction and hazard assessment from the 2004 Parkfield earthquake

Obtaining high-quality measurements close to a large earthquake is not easy: one has to be in the right place at the right time with the right instruments. Such a convergence happened, for the first time, when the 28 September 2004 Parkfield, California, earthquake occurred on the San Andreas fault in the middle of a dense network of instruments designed to record it. The resulting data reveal aspects of the earthquake process never before seen. Here we show what these data, when combined with data from earlier Parkfield earthquakes, tell us about earthquake physics and earthquake prediction. The 2004 Parkfield earthquake, with its lack of obvious precursors, demonstrates that reliable short-term earthquake prediction still is not achievable. To reduce the societal impact of earthquakes now, we should focus on developing the next generation of models that can provide better predictions of the strength and location of damaging ground shaking.     

The Contribution of Innovation Strategy Development and Implementation in Active Facilitation of Pharmaceutical Front End Innovation

Front end innovation (FEI) represents the first building blocks of product development, but is often regarded as a weak link in innovation literature. Various theorists emphasize that a firm??s innovation can benefit substantially by improving the front end of innovation process (Reinertsen, Res Technol Manag 42:23?C31, 1999; Stevens and Burly, Res Technol Manag 46(2):16?C25, 2003; Verworn et al., R&D Manag 38(1):1?C19, 2008) and that innovation strategies play a central role in optimization of innovation (Clark and Wheelwright, Leading product development, Free Press, New York, 1995; Cottam et al., Eur J Innov Manag 4:88?C94, 2001; Morgan and Berthon, J Manag Stud 45(8):1329?C1353, 2008). Innovation strategies are suggested in literature (e.g. Page, J Prod Innov Manag 10:273?C287, 1993; Oke, J Change Manag 2(3):272?C281, 2002; Adams et al., Int J Manag Rev 8(1):21?C47, 2006; Igartua et al., Res Technol Manag May?CJune:41?C52, 2010) as a facilitator of innovation and may therefore also be targeted at FEI support. The pharmaceutical industry has experienced a worldwide decline in the number of applications for new molecular entities to regulatory agencies since 1997. Therefore high pressures are put on pharmaceutical research and FEI to produce more valid candidates and faster for drug development. This paper explores how pharmaceutical FEI can be actively supported through the development and implementation of an innovation strategy. The empirical field and applied methodology is an action oriented longitudinal case study of a Danish pharmaceutical company. The findings and key learnings from the study are presented as propositions of how innovation strategies can be applied to actively facilitate FEI and with measurable results.